Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

ClinicalTrials.gov ID: NCT00893867

Public ClinicalTrials.gov record NCT00893867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is effective in improving long term outcome. Patients will be followed up for 3 months after the stroke.

Study identification

NCT ID
NCT00893867
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
D-Pharm Ltd.
Industry
Enrollment
446 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
Mar 31, 2012
Completion
Mar 31, 2012
Last update posted
Oct 23, 2012

2009 – 2012

United States locations

U.S. sites
13
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
Research Center of Southern California Oceanside California
Associated Neurologists, P.C. Danbury Connecticut
Memorial Health University Medical Center Savannah Georgia
The University of Kentucky The Methodist Hospital Lexington Kentucky
University of Louisville, Kentucky Neuroscience Research Louisville Kentucky
Tufts Medical Center Boston Massachusetts
Capital Health Regional Medical Center Neuroscience Institute Trenton New Jersey
Presbitarian Hospital Charlotte North Carolina
St. Elizabeth's Medical Center Youngstown Ohio
Legacy Meridian Park Medical Center Tualatin Oregon
Thomas Jefferson University Philadelphia Pennsylvania
The Methodist Hospital Houston Texas
Carilion Clinic Roanoke Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00893867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2012 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00893867 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →